Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncopeptides ABCHIX:ONCOS 46 12-1 Month Momentum % is -68.24% as of Jul. 29, 2026. GuruFocus rates CHIX:ONCOS with a GF Score™ of 46/100 and a GF Value™ of kr5.80 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,361 Biotechnology companies, Oncopeptides AB ranks worse than 88.17% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-29), Oncopeptides AB's 12-1 Month Momentum % is -68.24%.
The industry rank for Oncopeptides AB's 12-1 Month Momentum % or its related term are showing as below:
CHIX:ONCOs's 12-1 Month Momentum % is ranked worse than 88.17% of 1361
companies
in the Biotechnology industry
Industry Median: -20.29
vs CHIX:ONCOs: -68.24
Oncopeptides AB (CHIX:ONCOs) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Oncopeptides AB 12-1 Month Momentum % Related Terms
CHIX:ONCOS vs VRTX, REGN, RVMD: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Oncopeptides AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's 12-1 Month Momentum % falls into.
Oncopeptides AB (CHIX:ONCOs) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -68.24% mean?
Oncopeptides AB (CHIX:ONCOS) has a 12-1 Month Momentum % of -68.24% as of Jul. 29, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #1200 out of 1361 companies in the Biotechnology industry, placing it in the top 88.2%.
Is Oncopeptides AB's 12-1 Month Momentum % too high?
Oncopeptides AB's current 12-1 Month Momentum % is -68.24%. Based on the distribution chart, Oncopeptides AB ranks #1200 out of 1361 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #1200 out of 1361 companies for 12-1 Month Momentum %. This places Oncopeptides AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current 12-1 Month Momentum % is -68.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (CHIX:ONCOS) is currently considered Possible Value Trap. The stock's GF Value™ is kr5.80, compared to a current price of kr1.72 — trading 70.3% below its estimated fair value. The current 12-1 Month Momentum % is -68.24%. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Oncopeptides AB (CHIX:ONCOS), the current 12-1 Month Momentum % is -68.24% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (CHIX:ONCOS) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of kr1.72 is trading 70.3% below its estimated GF Value™ of kr5.80.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for CHIX:ONCOS:
12-1 Month Momentum %: -68.24%
GF Value™: kr5.80 vs. price of kr1.72 (70.3% below fair value)
No single metric tells the full story. See the CHIX:ONCOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score
Get the complete analysis for CHIX:ONCOS
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCOS has been successfully added to your 
